How the BxChip™ Delivers 60% Higher Grading Accuracy
In the world of prostate cancer, the Gleason score is the gold standard for treatment decisions. It’s the compass that guides urologists and patients toward either active surveillance or immediate intervention. But what happens when that compass is off?
A study published in the Romanian Journal of Urology (Vol 21, 2022) reveals a sobering reality: traditional biopsy methods often fail to capture the full picture. More importantly, the study highlights how Lumea’s BxChip is closing that gap, offering a significant leap in diagnostic accuracy.
The “Under-Staging” Problem
The study, conducted at the Clinical Hospital of Urology, compared 341 patients to see how well their initial biopsy scores matched their final surgical results (radical prostatectomy).
In the group using conventional biopsy methods, the results were alarming. Only 43% of biopsies accurately matched the final surgical grade. Patients were 1.5 times more likely to have their cancer undervalued (downstaged) compared to the BxChip group.
When a biopsy under-represents the severity of the disease, it can lead to delayed treatment for a patient who needs it most.
Why the BxChip™ Changes the Game
The study found that the BxChip group achieved a 69% consistency rate (a massive improvement over the 43% seen with classic methods.)
The researchers identified three key reasons for this success:
- Traditional processing often causes tissue to twist or break. The BxChip keeps cores straight and intact.
- By keeping cores on an even plane, which reduces linear variability, pathologists can see significantly more tissue on every slide.
- The study showed that BxChip scores were statistically more consistent across all grading categories, including Gleason patterns and ISUP scores.
Better Data, Better Decisions
For uropathologists, the BxChip provides a cleaner, more reliable canvas for diagnosis. For urologists, it provides the confidence that the treatment plan is based on the most accurate data possible. But most importantly, for the patient, it means a diagnosis they can trust.
“The use of BxChip in routine medical practice is a real innovation in the correct classification of prostate cancer.”
At Lumea, we are proud to see our technology validated by independent researchers who share our mission to eliminate diagnostic uncertainty and improve patient outcomes.
Interested in seeing how the BxChip can transform your lab’s precision and efficiency? Request a demo today.
*Tomosoiu, R.B., et al. (2022). Parallel Processing of Biopsies Increases Precision of Diagnosis in Prostate Cancer. Romanian Journal of Urology, 21(1).
